Improving clinical care of diabetes mellitus; randomized clinical trial

Impact of Ascorbic acid and Acetylsalicylic acid on the relative outcome of diabetes mellitus; multicenter single blinded randomized control trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON23763

Enrollment

300

Registered

2016-10-20

Start date

2015-11-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus

Interventions

a. control arm - metformin (500mgBD) usual dose b. Group 1 - randomized - metformin (500mgBD) + Ascobic acid (500mg OD) - for 12 months c. Group 2 - randomized - metformin (500mg BD) + Acetylsalicyl

Eligibility

Inclusion criteria

Inclusion criteria: a. patient age more than 18years b. diagnose with diabetes mellitus type 2 not more than 5 years c. both male/female d. prescribed with metformin 500mg BD dosing e. glucose intolerance with last 3 reading of FBS or SBG f. HbA1c more than 7% with minimum last 6 months g. only diagnosed with diabetes mellitus type 2.

Exclusion criteria

Exclusion criteria: a. patient with age less than 18 years b. diabetes history of more than 5 years c. transexual d. metformin dose more than 1 g/day or in-combination e. HbA1c less than 7% with last two readings f. patients with another systemic complications except diabetes mellitus type 2.

Design outcomes

Primary

Measure	Time frame
a. improved glucose tolerance b. Reduction in lipid profiling	—

Secondary

Measure	Time frame
a. Reduction in diabetes related complications over a period of 12 months b. Improved clinical outcomes in lipid profiling. c. comparison between Ascorbic acid Vs Acetylsalicylic acid combination with metformin.	—

Contacts

Public ContactSyed Wasif Gillani

Taibah University

wasifgillani@gmail.com

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)